236406-55-6

Basic information

• Product Name: 2-(tert-Butoxycarbonyl)-2,7-diazaspiro[3.5]nonane
• Synonyms: 2-(tert-Butoxycarbonyl)-2,7-diazaspiro[3.5]nonane;tert-butyl 2,7-diazaspiro[3.5]nonane-2-carboxylate;tert-Butyl 2,7-diazaspiro...;2,7-Diazaspiro[3.5]nonane-2-carboxylic acid, 1,1-diMethylethyl ester;2-BOC-2,7-DIAZASPIRO[3.5]NONANE;7-BOC-2,7-DIAZASPIRO[3.5]NONANE;tert-butyl 2,7-diazaspiro[3.5]nonane-2-carboxylate, hemioxalate salt
• CAS NO: 236406-55-6
• Molecular Formula: C12H22N2O2
• Molecular Weight: 226.32
• Mol File: 236406-55-6.mol

Chemical Properties

• Boiling Point: 319.425 °C at 760 mmHg
• Flash Point: 146.983 °C
• Appearance: /
• Density: 1.089 g/cm³
• Vapor Pressure: 0.000339mmHg at 25°C
• Refractive Index: 1.517
• Storage Temp.: 2-8°C(protect from light)
• PKA: 10.78±0.20(Predicted)
• CAS DataBase Reference: 2-(tert-Butoxycarbonyl)-2,7-diazaspiro[3.5]nonane(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(tert-Butoxycarbonyl)-2,7-diazaspiro[3.5]nonane(236406-55-6)
• EPA Substance Registry System: 2-(tert-Butoxycarbonyl)-2,7-diazaspiro[3.5]nonane(236406-55-6)

Safety Data

• Hazard Codes: T
• Statements: 52-25
• Safety Statements: 45
• Hazardous Substances Data: 236406-55-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(tert-Butoxycarbonyl)-2,7-diazaspiro[3.5]nonane is used as a synthetic reagent for the development of potent GPR119 agonists. These agonists are of significant interest due to their potential role in regulating glucose homeostasis and insulin secretion, making them valuable in the treatment of type 2 diabetes and other metabolic disorders.
Additionally, the compound may be utilized in the design and synthesis of other bioactive molecules targeting different receptors or enzymes, further expanding its applications in the pharmaceutical industry.

InChI:InChI=1/C12H22N2O2/c1-11(2,3)16-10(15)14-6-4-12(5-7-14)8-13-9-12/h13H,4-9H2,1-3H3

Upstream product

• 929301-99-5 tert-butyl 7-benzyl-2,7-diazaspiro[3.5]nonane-2-carboxylate 

Downstream Products

• 1257881-62-1 2-[3-(4-chloro-phenoxy)-benzyl]-2,7-diaza-spiro[3.5]nonane-7-carboxylic acid pyridin-3-ylamide 
• 1257881-97-2 7-[3-(4-chloro-phenoxy)-benzyl]-2,7-diaza-spiro[3.5]nonane-2-carboxylic acid (6-[1,2,3]triazol-2-yl-pyridin-3-yl)-amide 
• 1257881-96-1 7-[3-(4-chloro-phenoxy)-benzyl]-2,7-diaza-spiro[3.5]nonane-2-carboxylic acid benzo[d]isoxazol-3-ylamide 
• 1257881-87-0 7-(3-(4-chlorophenoxy)benzyl)-N-(imidazo[1,2-a]pyridin-3-yl)-2,7-diazaspiro[3.5]nonane-2-carboxamide 
• 1257881-86-9 7-(3-(4-chlorophenoxy)benzyl)-N-(imidazo[1,2-b]pyridazin-3-yl)-2,7-diazaspiro[3.5]nonane-2-carboxamide 
• 1257882-22-6 C₂₇H₂₆ClN₅O₃ 
• 1257882-84-0 7-(3-(4-chlorophenoxy)benzyl)-N-(4-methylpyridin-3-yl)-2,7-diazaspiro[3.5]nonane-2-carboxamide 
• 1257882-85-1 7-(3-(4-chlorophenoxy)benzyl)-N-(4-(trifluoromethyl)pyridin-3-yl)-2,7-diazaspiro[3.5]nonane-2-carboxamide 
• 1257882-83-9 7-(3-(4-chlorophenoxy)benzyl)-N-(4-cyanopyridin-3-yl)-2,7-diazaspiro[3.5]nonane-2-carboxamide 

Relevant articles and documents

SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS

The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.